1921
Volume 102, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) are endemic diseases in America, especially in some countries such as Colombia. Among the therapeutic options is amphotericin B (AB). Nevertheless, its lipid-associated formulations have better safety profiles and effectiveness in other diseases, so far with no comparative studies in CL or MCL. We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL. The effectiveness of LAB (88.5%) was greater than those of ABCD (66.6%) and ABD (80.8%). There were also fewer adverse effects in the LAB group (46.2%) than in the ABD (96.1%) and ABCD (80.9%) groups. LAB is an alternative for the treatment of CL and MCL in patients with therapeutic failure to first- and second-line drugs; findings suggest it might be less toxic and more effective than ABD and ABCD.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0514
2019-12-09
2021-01-16
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/2/tpmd180514.html?itemId=/content/journals/10.4269/ajtmh.18-0514&mimeType=html&fmt=ahah

References

  1. Von Stebut E, 2007. Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 17: 115122.
    [Google Scholar]
  2. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BPD, Nakamura CV, 2011. Recent advances in leishmaniasis treatment. Int J Infect Dis 15: e525e532.
    [Google Scholar]
  3. Pearson RD, Sousa AQ, 1996. Clinical spectrum of leishmaniasis. Clin Infect Dis 22: 113.
    [Google Scholar]
  4. Kevric I, Cappel MA, Keeling JH, 2015. New World and Old World leishmania infections. Dermatol Clin 33: 579593.
    [Google Scholar]
  5. World Health Organization, 2012. Control of Leishmaniasis: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniasis [in Spanish]. March 22–26, 2010, Geneva, Switzerland: WHO, (Technical Report Series), 200.
    [Google Scholar]
  6. Arevalo J et al., 2007. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 195: 18461851.
    [Google Scholar]
  7. Perez-Franco JE, Cruz-Barrera ML, Robayo ML, Lopez MC, Daza CD, Bedoya A, Mariño ML, Saavedra CH, Echeverry MC, 2016. Clinical and parasitological features of patients with American cutaneous leishmaniasis that did not respond to treatment with meglumine antimoniate. PLoS Negl Trop Dis 10: e0004739.
    [Google Scholar]
  8. Pan American Health Organization PAHO/WHO, Colombia Ministry of Social Protection, 2010. Comprehensive Care Guide for Leishmaniasis 2010 [in Spanish] [Internet]. Available at: http://www.vigepi.com.co/3salpub/5guias/guias/420g%20lei.pdf. Accessed May 18, 2015.
    [Google Scholar]
  9. World Health Organization/PanAmerican Health Organization, 2013. Leishmaniasis in the Americas. Recommendations for the Treatment; 2013. Geneva, Switzerland: WHO. Available at: https://www.who.int/neglected_diseases/resources/978-92-75-31752-5/en/.
    [Google Scholar]
  10. Saravia NG, Fernández Olga DY, Muvdi Sandra VL, 2011. Susceptibility of clinical strains of Leishmania to pentavalent antimony and miltefosine: challenges and opportunities. Biomédica 31 (Suppl 3): 3315.
    [Google Scholar]
  11. Croft SL, Sundar S, Fairlamb AH, 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111126.
    [Google Scholar]
  12. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG, 2006. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 193: 13751383.
    [Google Scholar]
  13. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Neto VA, 2008. Treatment of New World cutaneous leishmaniasis–a systematic review with a meta-analysis. Int J Dermatol 47: 109124.
    [Google Scholar]
  14. Sundar S, Chakravarty J, 2013. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother 14: 5363.
    [Google Scholar]
  15. Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, Weintrob A, Magill A, 2010. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 83: 10281033.
    [Google Scholar]
  16. Hamill RJ, 2013. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 73: 919934.
    [Google Scholar]
  17. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, Milani B, Gaspani S, Potet J, Chappuis F, 2012. Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17: 493510.
    [Google Scholar]
  18. Cunha MA, Leao ACQ, de Cassia Soler R, Lindoso JAL, 2015. Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the new world: a retrospective study. Am J Trop Med Hyg 93: 12141218.
    [Google Scholar]
  19. Pan American Health Organization, 2017. Epidemiological report of the americas. Leishmaniases. Washington, DC: Pan American Health Organization. Available at: http://iris.paho.org/xmlui/handle/123456789/34856?locale-attribute=es.
    [Google Scholar]
  20. Botero MC, Puentes-Herrera M, Cortés JA, 2014. Formas lipídicas de anfotericina [Lipid forms of amphotericin]. Rev Chil Infectol. 31: 518527.
    [Google Scholar]
  21. Elmahallawy EK, Sampedro Martinez A, Rodriguez-Granger J, Hoyos-Mallecot Y, Agil A, Navarro Mari JM, Gutierrez Fernandez J, 2014. Diagnosis of leishmaniasis. J Infect Dev Ctries 8: 961972.
    [Google Scholar]
  22. Patel R, 2000. Amphotericin B colloidal dispersion. Expert Opin Pharmacother 1: 475488.
    [Google Scholar]
  23. Wijnant G-J, Van Bocxlaer K, Yardley V, Harris A, Murdan S, Croft SL, 2018. AmBisome® treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy. Antimicrob Agents Chemother 62: e02009e02017.
    [Google Scholar]
  24. Purkait B et al., 2012. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother 56: 10311041.
    [Google Scholar]
  25. Al-Mohammed HI, Chance ML, Bates PA, 2005. Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana. Antimicrob Agents Chemother 49: 32743280.
    [Google Scholar]
  26. Guery R et al., 2017. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: not a panacea. PLoS Negl Trop Dis 20: e0006094.
    [Google Scholar]
  27. Ponte-Sucre A, Diaz E, Padrón-Nieves M, 2013. Drug Resistance in Leishmania Parasites: Consequences, Molecular Mechanisms and Possible Treatments. Wien, Austria: Springer-Verlag. Available at: //www.springer.com/us/book/9783709102381. Accessed February 12, 2018.
    [Google Scholar]
  28. O’Grady NP et al., 2011. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 39 (Suppl 1): S1S34.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0514
Loading
/content/journals/10.4269/ajtmh.18-0514
Loading

Data & Media loading...

  • Received : 19 Jun 2018
  • Accepted : 27 Sep 2019
  • Published online : 09 Dec 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error